作者采用双盲安慰剂对照法评价了低分子量肝素-FraxiParine（FE）治疗急性缺血性卒中的利弊。55例急性卒中患者作为本研究对象。年龄在30～80岁（平均64岁）。所有患者均在发病48小时内住院治疗。男性29例、女性26例。头颅CT，均排除了脑出血。FE的用法为，每天6000IU皮下注射 The authors evaluated the pros and cons of low molecular weight heparin-FraxiParine (FE) for acute ischemic stroke using a double-blind placebo-controlled trial. 55 cases of acute stroke patients as the study object. Aged 30 to 80 years (mean 64 years). All patients were hospitalized within 48 hours of onset. 29 males and 26 females. Head CT, all rule out cerebral hemorrhage. The usage of FE is 6000 IU subcutaneously daily